Gius Named Interim Co-Leader
Women's Cancer Research Program
David Gius, MD, PhD
David Gius, MD, PhD, has been named Interim Co-Leader of the Women’s Cancer Research Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, while a nationwide search to identify the next permanent leader of the program is ongoing. Gius, a nationally recognized radiation oncologist and researcher, is a Professor in the Department of Radiation Oncology at Northwestern University Feinberg School of Medicine.
The Women’s Cancer Research Program(WCRP) embraces a multidisciplinary approach to integrate its basic, translational, and clinical components. The program seeks to define the common mechanisms responsible for the risk and progression of tumors arising from the reproductive tissues of women including the breast, ovary, endometrium, myometrium, uterine cervix and vagina. In doing so, the goals of the WCRP are to identify molecular markers that contribute to the disease process and outcome, to develop targeted molecular approaches, and to translate these agents from pre-clinical models to the bedside.
In collaboration with Co-Leader Seema Khan, MD, Gius will increase the Women’s Cancer Research Program’s translational research activity. “David is an outstanding researcher and physician scientist who has made major contributions in the field of breast cancer research. His research is of very high quality and has been consistently funded by the National Cancer Institute,” said Leonidas Platanias, MD, PhD, Interim Director of the Lurie Cancer Center.
Gius’ laboratory research concentrates on the connection between aging, cellular metabolism and cancer, focusing on the role that the Sirtuin gene family plays in regulating a cell’s ability to recover from stress. In other laboratory studies, Gius is testing chemical agents that could yield promising new drug treatments for women with receptor-positive breast cancer.
Gius joined Northwestern in 2012 from Vanderbilt University’s Ingram Cancer Center. He has published more than 90 peer-reviewed manuscripts in many prestigious journals, including Nature, Cancer Cell, Science, Molecular Cell, PNAS, Molecular and Cellular Biology, and Cancer Research. His research is funded by three R01 grants from the NCI, and he is a member of the National Institutes of Health Radiation and Therapeutics and Biology Study Section.
(Last updated on February 19, 2014 )